Tirtha Chanda

Tirtha Chanda

Auto-generated profile, based on publicly available information

Tirtha Chanda

Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTirtha Chanda
Tirtha Chanda
KHKatja Hauser
Katja Hauser
SHSarah Hobelsberger
Sarah Hobelsberger
TBTabea-Clara Bucher
Tabea-Clara Bucher
CGCarina Nogueira Garcia
Carina Nogueira Garcia
TBTitus Josef Brinker
Titus Josef Brinker
Artificial intelligence (AI) systems have been shown to help dermatologists diagnose melanoma more accurately, however they lack transparency, hindering user acceptance. Explainable AI (XAI) methods can help to increase transparency, yet often lack precise, domain-specific explanations. Moreover, the impact of XAI methods on dermatologists’ decisions has not yet been evaluated. Building upon previous research, we introduce an XAI system that provides precise and domain-specific explanations alongside its differential diagnoses of melanomas and nevi. Through a three-phase study, we assess its impact on dermatologists’ diagnostic accuracy, diagnostic confidence, and trust in the XAI-support. Our results show strong alignment between XAI and dermatologist explanations. We also show that dermatologists’ confidence in their diagnoses, and their trust in the support system significantly increase with XAI compared to conventional AI. This study highlights dermatologists’ willingness to adopt such XAI systems, promoting future use in the clinic.

21 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTirtha Chanda
Tirtha Chanda
SHSarah Haggenmueller
Sarah Haggenmueller
TBTabea-Clara Bucher
Tabea-Clara Bucher
THTim Holland-Letz
Tim Holland-Letz
HKHARALD KITTLER
HARALD KITTLER
TBTitus Josef Brinker
Titus Josef Brinker
Artificial intelligence (AI) systems substantially improve dermatologists’ diagnostic accuracy for melanoma, with explainable AI (XAI) systems further enhancing their confidence and trust in AI-driven decisions. Despite these advancements, there remains a critical need for objective evaluation of how dermatologists engage with both AI and XAI tools. In this study, 76 dermatologists participate in a reader study, diagnosing 16 dermoscopic images of melanomas and nevi using an XAI system that provides detailed, domain-specific explanations, while eye-tracking technology assesses their interactions. Diagnostic performance is compared with that of a standard AI system lacking explanatory features. Here we show that XAI significantly improves dermatologists’ diagnostic balanced accuracy by 2.8 percentage points compared to standard AI. Moreover, diagnostic disagreements with AI/XAI systems and complex lesions are associated with elevated cognitive load, as evidenced by increased ocular fixations. These insights have significant implications for the design of AI/XAI tools for visual tasks in dermatology and the broader development of XAI in medical diagnostics.

8 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GMGesa Mittmann
Gesa Mittmann
SLSara Laiouar-Pedari
Sara Laiouar-Pedari
HMHendrik A. Mehrtens
Hendrik A. Mehrtens
SHSarah Haggenmüller
Sarah Haggenmüller
TBTabea-Clara Bucher
Tabea-Clara Bucher
TBTitus Josef Brinker
Titus Josef Brinker
The aggressiveness of prostate cancer is primarily assessed from histopathological data using the Gleason scoring system. Conventional artificial intelligence (AI) approaches can predict Gleason scores, but often lack explainability, which may limit clinical acceptance. Here, we present an alternative, inherently explainable AI that circumvents the need for post-hoc explainability methods. The model was trained on 1,015 tissue microarray core images, annotated with detailed pattern descriptions by 54 international pathologists following standardized guidelines. It uses pathologist-defined terminology and was trained using soft labels to capture data uncertainty. This approach enables robust Gleason pattern segmentation despite high interobserver variability. The model achieved comparable or superior performance to direct Gleason pattern segmentation (Dice score: $${0.713}_{\pm 0.003}$$ 0.713 ± 0.003 vs. $${0.691}_{\pm 0.010}$$ 0.691 ± 0.010 ) while providing interpretable outputs. We release this dataset to encourage further research on segmentation in medical tasks with high subjectivity and to deepen insights into pathologists’ reasoning.

13 August 2026 in European Journal of Cancer
Verified
Journal Article
Open access
NMNicolas B. Merl
Nicolas B. Merl
JWJana Winterstein
Jana Winterstein
FSFranziska Schramm
Franziska Schramm
TCTirtha Chanda
Tirtha Chanda
CWChristoph Wies
Christoph Wies
TBTitus Josef Brinker
Titus Josef Brinker